Cargando…
Humoral response to SARS-CoV-2 vaccines in people living with HIV
PURPOSE: To describe the humoral immune response to COVID-19 vaccines in people living with HIV and identify factors associated with the magnitude of anti-SARS-CoV-2 antibody concentrations. METHODS: Retrospective analysis of electronic patient files in a big single HIV center in Munich, Germany. No...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8543429/ https://www.ncbi.nlm.nih.gov/pubmed/34694595 http://dx.doi.org/10.1007/s15010-021-01721-7 |
_version_ | 1784589634009825280 |
---|---|
author | Noe, Sebastian Ochana, Nino Wiese, Carmen Schabaz, Farhad Von Krosigk, Ariane Heldwein, Silke Rasshofer, Rudolf Wolf, Eva Jonsson-Oldenbuettel, Celia |
author_facet | Noe, Sebastian Ochana, Nino Wiese, Carmen Schabaz, Farhad Von Krosigk, Ariane Heldwein, Silke Rasshofer, Rudolf Wolf, Eva Jonsson-Oldenbuettel, Celia |
author_sort | Noe, Sebastian |
collection | PubMed |
description | PURPOSE: To describe the humoral immune response to COVID-19 vaccines in people living with HIV and identify factors associated with the magnitude of anti-SARS-CoV-2 antibody concentrations. METHODS: Retrospective analysis of electronic patient files in a big single HIV center in Munich, Germany. Non-parametric methods were used for descriptive and comparative statistics. Generalized linear models were used to analyze associations of general and HIV-specific variables with anti-SARS-CoV-2 antibody concentrations after standard vaccination. RESULT: Overall, 665 people living with HIV were included into the analysis (median age: 53 [IQR: 43; 59]), 560 [84.2%] males). Median concentration of anti-SARS-CoV-2-antibodies was 1400 (IQR 664; 2130) BAU/mL. In 18 (2.7%) subjects, antibody concentrations below the threshold of 34 BAU/mL were found. Among PLWH with CD4 cell count < 200 cells/µL, median anti-SARS-CoV-2-Abs were 197 (IQR 44.6; 537.2) as compared to 1420 (IQR 687; 2216) for the group ≥ 200 cells/µL (p < 0.001). In a cumulative logit model, a vaccination scheme including an mRNA vaccine [OR: 4.64 (3.58; 6.02)], being female [OR: 2.14 (1.76; 2.61)], and having higher CD4 cells [OR per 100 cells/µL: 1.06 (1.04; 1.08)] were significantly associated with anti-SARS-CoV-2 antibody concentrations in higher quartiles, when adjusted for the time after vaccination. CONCLUSION: We found a robust antibody response in people living with HIV undergoing standard vaccination against SARS-CoV-2. mRNA-containing vaccination schemes, being female, and having a higher CD4 cell count was associated with a higher concentration of antibodies in people living with HIV in our study sample. Particularly in the subgroup with CD4 cell counts < 200 cells/µL, antibody response was poor. |
format | Online Article Text |
id | pubmed-8543429 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-85434292021-10-25 Humoral response to SARS-CoV-2 vaccines in people living with HIV Noe, Sebastian Ochana, Nino Wiese, Carmen Schabaz, Farhad Von Krosigk, Ariane Heldwein, Silke Rasshofer, Rudolf Wolf, Eva Jonsson-Oldenbuettel, Celia Infection Original Paper PURPOSE: To describe the humoral immune response to COVID-19 vaccines in people living with HIV and identify factors associated with the magnitude of anti-SARS-CoV-2 antibody concentrations. METHODS: Retrospective analysis of electronic patient files in a big single HIV center in Munich, Germany. Non-parametric methods were used for descriptive and comparative statistics. Generalized linear models were used to analyze associations of general and HIV-specific variables with anti-SARS-CoV-2 antibody concentrations after standard vaccination. RESULT: Overall, 665 people living with HIV were included into the analysis (median age: 53 [IQR: 43; 59]), 560 [84.2%] males). Median concentration of anti-SARS-CoV-2-antibodies was 1400 (IQR 664; 2130) BAU/mL. In 18 (2.7%) subjects, antibody concentrations below the threshold of 34 BAU/mL were found. Among PLWH with CD4 cell count < 200 cells/µL, median anti-SARS-CoV-2-Abs were 197 (IQR 44.6; 537.2) as compared to 1420 (IQR 687; 2216) for the group ≥ 200 cells/µL (p < 0.001). In a cumulative logit model, a vaccination scheme including an mRNA vaccine [OR: 4.64 (3.58; 6.02)], being female [OR: 2.14 (1.76; 2.61)], and having higher CD4 cells [OR per 100 cells/µL: 1.06 (1.04; 1.08)] were significantly associated with anti-SARS-CoV-2 antibody concentrations in higher quartiles, when adjusted for the time after vaccination. CONCLUSION: We found a robust antibody response in people living with HIV undergoing standard vaccination against SARS-CoV-2. mRNA-containing vaccination schemes, being female, and having a higher CD4 cell count was associated with a higher concentration of antibodies in people living with HIV in our study sample. Particularly in the subgroup with CD4 cell counts < 200 cells/µL, antibody response was poor. Springer Berlin Heidelberg 2021-10-25 2022 /pmc/articles/PMC8543429/ /pubmed/34694595 http://dx.doi.org/10.1007/s15010-021-01721-7 Text en © The Author(s), under exclusive licence to Springer-Verlag GmbH Germany 2021 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | Original Paper Noe, Sebastian Ochana, Nino Wiese, Carmen Schabaz, Farhad Von Krosigk, Ariane Heldwein, Silke Rasshofer, Rudolf Wolf, Eva Jonsson-Oldenbuettel, Celia Humoral response to SARS-CoV-2 vaccines in people living with HIV |
title | Humoral response to SARS-CoV-2 vaccines in people living with HIV |
title_full | Humoral response to SARS-CoV-2 vaccines in people living with HIV |
title_fullStr | Humoral response to SARS-CoV-2 vaccines in people living with HIV |
title_full_unstemmed | Humoral response to SARS-CoV-2 vaccines in people living with HIV |
title_short | Humoral response to SARS-CoV-2 vaccines in people living with HIV |
title_sort | humoral response to sars-cov-2 vaccines in people living with hiv |
topic | Original Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8543429/ https://www.ncbi.nlm.nih.gov/pubmed/34694595 http://dx.doi.org/10.1007/s15010-021-01721-7 |
work_keys_str_mv | AT noesebastian humoralresponsetosarscov2vaccinesinpeoplelivingwithhiv AT ochananino humoralresponsetosarscov2vaccinesinpeoplelivingwithhiv AT wiesecarmen humoralresponsetosarscov2vaccinesinpeoplelivingwithhiv AT schabazfarhad humoralresponsetosarscov2vaccinesinpeoplelivingwithhiv AT vonkrosigkariane humoralresponsetosarscov2vaccinesinpeoplelivingwithhiv AT heldweinsilke humoralresponsetosarscov2vaccinesinpeoplelivingwithhiv AT rasshoferrudolf humoralresponsetosarscov2vaccinesinpeoplelivingwithhiv AT wolfeva humoralresponsetosarscov2vaccinesinpeoplelivingwithhiv AT jonssonoldenbuettelcelia humoralresponsetosarscov2vaccinesinpeoplelivingwithhiv |